stockrow
Friday 6 November 2026
Export BEAM’s income statement to Excel — free account
Beam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −16.7%
- Free cash flow
- −29.5%
Quarter to September 2026, against a year earlier
26.09
0.22
+0.85%
Follow BEAM
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
19.62 | 15.00 | 22.95 | 17.46 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(32.92) | (19.15) | (54.17) | (23.11) | |
P/B ratio |
2.21 | 2.11 | 3.35 | 2.69 | |
Price to Tangible BV |
2.21 | 2.11 | 3.35 | 2.69 | |
EV/Sales |
11.86 | 8.23 | 16.20 | 11.02 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.80) | (3.65) | (7.03) | (4.16) | |
EV/FCF |
(4.60) | (3.52) | (6.78) | (4.06) | |
Quick Ratio |
12.85 | 16.25 | 14.25 | 12.72 | |
Current Ratio |
13.09 | 16.99 | 14.57 | 13.00 | |
Net Debt/EBITDA |
82.82 | 10.65 | 8.51 | 6.81 | |
Debt/Assets |
0.00% | 6.77% | 7.23% | 7.91% | |
Debt/Equity |
0.00 | 0.09 | 0.09 | 0.11 | |
Asset Turnover |
0.11 | 0.11 | 0.11 | 0.11 | |
Operating CF/Net income |
(0.34) | 1.36 | 0.54 | 0.82 | |
Capex/Depreciation |
(1.55) | (0.78) | (0.84) | (0.45) | |
Research and Development Expense of Revenue |
87.00% | 329.33% | 19,407.35% | 35,866.45% | |
Selling, General and Administrative Expense of Revenue |
28.29% | 108.48% | 6,519.80% | 10,266.78% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
17.92% | 60.00% | 3,934.29% | 6,043.97% | |
Graham Net Nets |
0.37 | 0.39 | 0.24 | 0.29 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(3.50%) | (2.69%) | (2.39%) | (4.11%) | |
Free Cash Flow Yield |
(13.13%) | (15.60%) | (10.41%) | (15.56%) | |
Revenue per Share |
1.15 | 0.31 | 0.00 | 0.00 | |
Operating CF per Share |
(0.84) | (1.24) | (0.63) | (1.06) | |
Capex per Share |
(0.04) | (0.02) | (0.02) | (0.01) | |
Free Cash Flow per Share |
(0.88) | (1.27) | (0.66) | (1.07) | |
Cash per Share |
12.59 | 11.73 | 11.05 | 9.97 | |
Shareholders Equity per Share |
12.52 | 11.28 | 10.23 | 9.10 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
12.52 | 11.28 | 10.23 | 9.10 | |
Free Cash Flow |
(87.02) | (130.74) | (68.51) | (111.96) | |
Working Capital |
1,171.75 | 1,192.39 | 1,097.71 | 985.30 | |
Capital Expenditures |
(3.73) | (2.23) | (2.41) | (1.21) | |
Net Current Asset Value |
1,025.87 | 950.59 | 859.68 | 750.98 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.07 | 4.93 | 3.94 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
7.05 | 9.99 | 11.83 | 14.85 | |
Average Assets |
1,292.50 | 1,473.86 | 1,388.76 | 1,290.08 | |
Average Common Equity |
985.95 | 1,143.79 | 1,057.13 | 959.34 |
Columns are period end dates · fundamentals updated 5 Nov 2026